{"name":"Acer Therapeutics Inc.","slug":"acer-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPSXMtUXZUYkczMmQtU3RYRkZDT0d3S2hQeUhwUDlUUzh5MDloWTlGb2NncWw4dU1ucEJ2aU1KWTFRYzNBQXFIWHFDZ1FydFhwUjNRdFZfcnNGb0Zja1R5NlRtT1ZhVGhQZWNQaU1DLVA3WGRWUWJjT3FLaWF0TUpLY1BXX3Q3RlZsTVZOZDQtaDJBOTdIV3ByX0FvOE5nc1hfa1NNYUNn?oc=5","date":"2025-08-13","type":"pipeline","source":"Investor's Business Daily","summary":"Zevra Therapeutics Crashes, Reversing 89% Run. Why It Could Be An 'Overreaction.' - Investor's Business Daily","headline":"Zevra Therapeutics Crashes, Reversing 89% Run. Why It Could Be An 'Overreaction.' - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxORW5YT3BDdDhwZG1kYjI5YWg2NWFsRDcwb21VX3RkbDFwcjZYcXQ4MFFKcEo2Zk5QeGdjd2UzWWo2b0c1NGUyZGFtdUpMMDRIaDVpRjVMRU05dlNtZ2Rja3ZSZVk5ZERoMFZfbUlsZWROZkpQNG9OX0dPN3Y3elhsazNJODl3VUVkbjNDVnFaaERnZ1E?oc=5","date":"2025-07-10","type":"regulatory","source":"The Business Journals","summary":"FDA publishes drug rejection letters for 15 Massachusetts biotechs - The Business Journals","headline":"FDA publishes drug rejection letters for 15 Massachusetts biotechs","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQSVpPWnJGWVdBc1lmMkpHNmV1ZkJhbTdnWjY2c0VPcllyWjBKUjh2U2dKNU1uZ0dYMkxQU29XUGN5cDVVOEh6R0R5QWJuSG8yYWtHbjVoMzh3ZnN3ZGpoR1N0V0I4OXFfWkExb21hTktCRzhqR3lLUG9SaU5tSlhrb2FUYy1meTR0MTJlcW5GZDJGdmg2UV9HZw?oc=5","date":"2024-12-09","type":"pipeline","source":"Pharma Voice","summary":"A drug for fewer than 1,000 patients? Awareness and diagnosis are key. - Pharma Voice","headline":"A drug for fewer than 1,000 patients? Awareness and diagnosis are key.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAJBVV95cUxQSmQwNEtpWnBhMXNKRDRWaU1oTE93dXV0dTR6eGZGcU5jSV9uTWRidTE2YnFsOVlldFl5T1liaG1oWDR1SWdITU5DMm1LNndhbTdYdDNMNl9iMEVPUVVTNld3bkg2c3JaSmdGRlQ4MEd0YXcxZXhnRHdsWVhqa3VrQzVWbTNPbUlQQkRZb2lUdXFvMDlPeVBhSmk3SjFyNTFrYzFZM2RoVDE0YlRtY0ZfSnRmcXJudW1nX1oxaTdkLTZHRjB6bm00dVM2N0w5bllIX0xQRFgtdWJ6ZkRVWkRGNENmMFJUdjgxa0lUX2k2WVo2QWR4bjJ1WDJoQVB0OTJ4NDZTaWh0T1UwOGdjVWNnbzkyVTlCY09EVERGdmFxdnVGMnNTWEMtVFF3OFpzeEJN?oc=5","date":"2024-12-03","type":"pipeline","source":"prnewswire.com","summary":"Urea Cycle Disorder Treatment Market to Grow by USD 215.4 Million (2024-2028), Driven by Rising Prevalence, with AI Redefining Market Landscape - Technavio - prnewswire.com","headline":"Urea Cycle Disorder Treatment Market to Grow by USD 215.4 Million (2024-2028), Driven by Rising Prevalence, with AI Rede","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTFBZMUpCZ1c5clNObmtydHdFWnNwUTRwX2lIQVdWRHZwSm9WQnZvM2N1S0lhUHdZcG9tZ2RaUDRfNm1oeTdYMTdld0pUODVzRzlaOVhXd0RSLWlmT1RRYkRIYm5CZmh6VHEwZnpUTWdwWkRhRk5sWUsxcWxR?oc=5","date":"2023-11-21","type":"deal","source":"Pharmaceutical Technology","summary":"Zevra Therapeutics completes Acer acquisition in $91m deal - Pharmaceutical Technology","headline":"Zevra Therapeutics completes Acer acquisition in $91m deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPb0xybEVYSnJzWE5ZSzdwUDQzWVpmdzhTNXRTbjVpbDd5TDhDeEc2NVdNZ0VRc25OSnYteWs3YUJhV0dsbl9hVG9udW1HV1NJUFMyTkVhNC1adGRES1RsbEFkX2R3MFliMW1YODZ2WjFOa2VlR09CUzBScGw1d2ktdW12dVFfMTR1cm5Qa3A2WTlkck5mQ2c?oc=5","date":"2023-11-20","type":"deal","source":"Contract Pharma","summary":"Zevra Therapeutics Acquires Acer Therapeutics - Contract Pharma","headline":"Zevra Therapeutics Acquires Acer Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPQnJtUXQydFdGb08zSTAxOEYtZjhCS3NiYTRsTDB5X2lENXIzTGs1MUNBRllqX3hNR1BRck5xZ0dka2FNU29xaUVyMGw3MWwwUHpQRjFSdXhBeEJqWTlTN2g2ZEFDTzNPVlZDZ3dmM21BMG9iaURqYk5lR3VoaGpjNWtIMWhYVUpVNTlDMkI3dW1MTWQ3cVA4ZmE4dmlUWTRlV19ucGpDbTk0dU43bjBJZg?oc=5","date":"2023-08-31","type":"deal","source":"Fierce Pharma","summary":"Zevra strikes $91M buyout of Acer to catapult itself into commercial rare disease space - Fierce Pharma","headline":"Zevra strikes $91M buyout of Acer to catapult itself into commercial rare disease space","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxOczRoc2pxdUFpR2czNWN3ZlMyNDZ4QlBsZWZTb1JKdHdfM2VLODRCbF9aNWFrd1BTeEdlTHBNTXZMTHRNTEdFWUQ1R0RhSUlxS1hrQXQycjJ0X05oTTJua3lDVW9RbTk1dkZUTlV2MjFVZHd4S3EtMTgtUDdtYW1CM2E1eFFYYmxydk9kWDRrQWZRZkx4b09xOUxSTXlrMlA5ZWx0aXFObzYyaVhEMnVNdUduSFRycEREdXlGSGo3Z1dKd2VvTk9CTHZ5eEgwT19ZRHNULThIU1RweUpSdVA1OWgxYUxxdk9lSktJNHhpWFJaR1JXdEhianlFb3BZanEzc3hJWURpaGJScG1qOGV3NGdON3AtMDdUYVE?oc=5","date":"2023-08-31","type":"deal","source":"GlobeNewswire","summary":"Zevra Therapeutics to Acquire Acer Therapeutics, Expanding - GlobeNewswire","headline":"Zevra Therapeutics to Acquire Acer Therapeutics, Expanding","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNc29EWjhxU0U0N210Sk9tVFF1RXpRenBkdTFZUjFhQjkzZ2ZFSnM2OG5ySTVwRklSUUR3MW5RdFNHZGJRd1BFM2YtTGpLZ193TUI2RDNYN3Z1ampzS3hudEhMeEhoR2NFRjZhS2xRUEpIOF9tR2tZRlI1MzJodjdPZjQ3TDJWOXZyLUdNR2E5ajZEUVg4bHZPSQ?oc=5","date":"2023-08-15","type":"pipeline","source":"The Business Journals","summary":"Acer Therapeutics, funded almost entirely by its own CEO, has weeks to live - The Business Journals","headline":"Acer Therapeutics, funded almost entirely by its own CEO, has weeks to live","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxPd0NxRzdfMXFMZ1FoLWtyYzlzbkRzSmtYbFBlc0N6WnN2NmJ3ajRfbXZ1QTNhMmlrY24yWWF1Rjc5MUxjMGI0MHk1YnMyTVFYQnZXSVdpZE9OS3IwbFZqejJfSkl1RnpBRVZpQTdhUjdPMWJoTTZZMVctRWtZU0ltQjYzY0M1SHBmVnVPUVdEZVRHVW5UR1JYQVBWNnZNaFpZNGl4UGpGNjZTNldzeGphYnpxR0s2ZklXa0FQd0RweGYxdGU4bDNmSHRqc0RnTkdhY0pyVU9HSEM1Qzdtb05Qa1RTckdQdzRra2kzc1dJcndxeU5uTU9ubGZyN1hQNEh2Nk5WbnFkdWs5bTdOcE1VX3BaaFJxZEF1?oc=5","date":"2022-12-27","type":"regulatory","source":"GlobeNewswire","summary":"Acer Therapeutics and Relief Therapeutics Announce U.S. FDA - GlobeNewswire","headline":"Acer Therapeutics and Relief Therapeutics Announce U.S. FDA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQNE1DN1hmdW9LMlpxSkthU1ZadUFsUnVhb2tmV3BDeWF0d3pRdVk0cjdma0szeHZkUzVxclBZcU1QdlRtWG1RNy1nOHRicGJiZVpCRjlRQjUtaXJtNkVMTDkwTVhKdWdFT0dody05Y0g0djhLdm5qcjQyRURqX1NaTHNmdEFtMUpBQUdRQlRTbzJqS2Q3LWNnbGR3OUxVTC1jU3FKT3pHSENzdS1MeDlnM0dTZVVHYWtkUW4tdXhKQV9IbVlVTkE?oc=5","date":"2022-12-23","type":"regulatory","source":"Reuters","summary":"U.S. FDA approves Acer Therapeutics' genetic disorder drug - Reuters","headline":"U.S. FDA approves Acer Therapeutics' genetic disorder drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPX3BlM1p4ZkY5WlA2UVFJMlUxd21VWjhDZ1h5T1d5cXpzRFhXZEpScUFRTEdHalpNSnhHYkUwMHdUSGdwT3pFdWFNRVNoYVVRdl8wM1l0ZlV5ZVl6NnFvaE11NjVpV3RzUFNqOGFMTUN5cWtydmR5UmFYcTFUdDBWaVl6VktsRUttNV95MG5pUkt0ZlExZzNMdVpDTHNDNnd4X1lVUDFjMjlMVVVpX2dkaW45aw?oc=5","date":"2022-06-27","type":"trial","source":"drugdiscoverytrends.com","summary":"Acer Therapeutics launches Phase 3 study for vascular Ehlers-Danlos syndrome - drugdiscoverytrends.com","headline":"Acer Therapeutics launches Phase 3 study for vascular Ehlers-Danlos syndrome","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}